Why DSIP Was the Only Peptide the FDA Panel Rejected

Across two days and seven peptides, the FDA's Pharmacy Compounding Advisory Committee said yes six times. The single exception came on July 24, 2026, when emideltide — delta sleep-inducing peptide, universally known in the research world as DSIP — was voted down 6–7 with one abstention. One vote separated it from the winners. Understanding why DSIP alone fell short says a lot about how this panel actually reasoned.

What DSIP Is

DSIP is a nonapeptide first isolated in the 1970s from rabbit brain during sleep research. It circulates endogenously and has been studied — mostly in small, older European trials — for sleep architecture, stress modulation, and withdrawal states. The uses the FDA formally evaluated at the July meeting were opioid withdrawal, chronic insomnia, and narcolepsy.

Why It Lost When the Others Won

The committee's six approvals all came over FDA staff objections — the panel repeatedly decided that thin evidence plus a harm-reduction rationale justified a recommendation. DSIP is the one case where the majority agreed with staff instead. Several factors distinguished it:

• The oldest, thinnest human data of the seven. DSIP's clinical literature is dominated by small trials from the 1980s with inconsistent results. Even by the forgiving standards this panel applied elsewhere, reviewers found the efficacy signal weakest here. FDA staff had flagged its studies as limited in both quantity and quality.
• A crowded, well-served indication. Insomnia and narcolepsy have multiple approved, well-characterized treatments. The access-gap argument that carried BPC-157 — patients turning to bodegas and gray-market vials because no sanctioned option exists — is much harder to make for sleep.
• The opioid-withdrawal claim raised stakes. Recommending an poorly characterized compound into a vulnerable withdrawal population is a different risk calculus than recommending a wound-healing peptide to biohackers. Caution won.

The One-Vote Margin Matters

What This Means for DSIP Research

Practically, nothing changed — which is also true of the six winners, just with a different emotional valence. DSIP was not legal to compound before July 24 and is not now. It remains available as a research compound, and the sleep-and-recovery research community will keep working with it regardless of the vote. What DSIP loses is the prospective pathway: while BPC-157 and friends now wait in the rulemaking queue, DSIP is not in line at all. A future nomination and re-vote is possible but nothing suggests one is imminent.

For researchers focused on sleep-adjacent peptides, note that Epitalon — which the FDA evaluated for insomnia — did clear the panel, 7–5. Our Epitalon profile covers the pineal-axis research that distinguishes it from DSIP mechanistically. And for the athlete's angle on sleep stacking after this vote, The Protocol at PowerPeptides has a recovery-focused take.